Overall Survival and Cause-specific Mortality in a Hospital-based Cohort of Retinoblastoma Patients in São Paulo, Brazil

Overview

Journal Int J Cancer

Specialty Oncology

Date 2024 Aug 14

PMID 39138799

Authors

Karina B Ribeiro

Lene H S Veiga

Nevicolino P Carvalho Filho

Lindsay M Morton

Ruth A Kleinerman

Celia B G Antoneli

Affiliations

Soon will be listed here.

Abstract

Studies are lacking on long-term effects among retinoblastoma patients in low- and middle-income countries. Therefore, we examined cause-specific mortality in a retrospective cohort of retinoblastoma patients treated at Antonio Candido de Camargo Cancer Center (ACCCC), São Paulo, Brazil from 1986 to 2003 and followed up through December 31, 2018. Vital status and cause of death were ascertained from medical records and multiple national databases. We estimated overall and cause-specific survival using the Kaplan-Meier survival method, and estimated standardized mortality ratios (SMRs) and absolute excess risk (AER) of death. This cohort study included 465 retinoblastoma patients (42% hereditary, 58% nonhereditary), with most (77%) patients diagnosed at advanced stages (IV or V). Over an 11-year average follow-up, 80 deaths occurred: 70% due to retinoblastoma, 22% due to subsequent malignant neoplasms (SMNs) and 5% to non-cancer causes. The overall 5-year survival rate was 88% consistent across hereditary and nonhereditary patients (p = .67). Hereditary retinoblastoma patients faced an 86-fold higher risk of SMN-related death compared to the general population (N = 16, SMR = 86.1, 95% CI 52.7-140.5), corresponding to 42.4 excess deaths per 10,000 person-years. This risk remained consistent for those treated with radiotherapy and chemotherapy (N = 10, SMR = 90.3, 95% CI 48.6-167.8) and chemotherapy alone (N = 6, SMR = 80.0, 95% CI 35.9-177.9). Nonhereditary patients had only two SMN-related deaths (SMR = 7.2, 95% CI 1.8-28.7). There was no excess risk of non-cancer-related deaths in either retinoblastoma form. Findings from this cohort with a high proportion of advanced-stage patients and extensive chemotherapy use may help guide policy and healthcare planning, emphasizing the need to enhance early diagnosis and treatment access in less developed countries.

References

Naseripour M . "Retinoblastoma survival disparity": The expanding horizon in developing countries. Saudi J Ophthalmol. 2013; 26(2):157-61. PMC: 3729846. DOI: 10.1016/j.sjopt.2012.02.003. View

Yu C, Tucker M, Abramson D, Furukawa K, Seddon J, Stovall M . Cause-specific mortality in long-term survivors of retinoblastoma. J Natl Cancer Inst. 2009; 101(8):581-91. PMC: 2669101. DOI: 10.1093/jnci/djp046. View

Kleinerman R, Tucker M, Sigel B, Abramson D, Seddon J, Morton L . Patterns of Cause-Specific Mortality Among 2053 Survivors of Retinoblastoma, 1914-2016. J Natl Cancer Inst. 2019; 111(9):961-969. PMC: 6748807. DOI: 10.1093/jnci/djy227. View

Marees T, van Leeuwen F, Schaapveld M, Imhof S, de Boer M, Kors W . Risk of third malignancies and death after a second malignancy in retinoblastoma survivors. Eur J Cancer. 2010; 46(11):2052-8. DOI: 10.1016/j.ejca.2010.03.029. View

Schonfeld S, Kleinerman R, Abramson D, Seddon J, Tucker M, Morton L . Long-term risk of subsequent cancer incidence among hereditary and nonhereditary retinoblastoma survivors. Br J Cancer. 2021; 124(7):1312-1319. PMC: 8007574. DOI: 10.1038/s41416-020-01248-y. View

Canturk S, Qaddoumi I, Khetan V, Ma Z, Furmanchuk A, Antoneli C . Survival of retinoblastoma in less-developed countries impact of socioeconomic and health-related indicators. Br J Ophthalmol. 2010; 94(11):1432-6. DOI: 10.1136/bjo.2009.168062. View

Fernandes A, Pollock B, Rabito F . Retinoblastoma in the United States: A 40-Year Incidence and Survival Analysis. J Pediatr Ophthalmol Strabismus. 2017; 55(3):182-188. DOI: 10.3928/01913913-20171116-03. View

Temming P, Arendt M, Viehmann A, Eisele L, Le Guin C, Schundeln M . How Eye-Preserving Therapy Affects Long-Term Overall Survival in Heritable Retinoblastoma Survivors. J Clin Oncol. 2016; 34(26):3183-8. DOI: 10.1200/JCO.2015.65.4012. View

Wong J, Morton L, Tucker M, Abramson D, Seddon J, Sampson J . Risk of subsequent malignant neoplasms in long-term hereditary retinoblastoma survivors after chemotherapy and radiotherapy. J Clin Oncol. 2014; 32(29):3284-90. PMC: 4178525. DOI: 10.1200/JCO.2013.54.7844. View

10.

Fabian I, Abdallah E, Abdullahi S, Abdulqader R, Boubacar S, Ademola-Popoola D . Global Retinoblastoma Presentation and Analysis by National Income Level. JAMA Oncol. 2020; 6(5):685-695. PMC: 7047856. DOI: 10.1001/jamaoncol.2019.6716. View

11.

Temming P, Arendt M, Viehmann A, Eisele L, Le Guin C, Schundeln M . Incidence of second cancers after radiotherapy and systemic chemotherapy in heritable retinoblastoma survivors: A report from the German reference center. Pediatr Blood Cancer. 2016; 64(1):71-80. DOI: 10.1002/pbc.26193. View

12.

Acquaviva A, Ciccolallo L, Rondelli R, Balistreri A, Ancarola R, Cozza R . Mortality from second tumour among long-term survivors of retinoblastoma: a retrospective analysis of the Italian retinoblastoma registry. Oncogene. 2006; 25(38):5350-7. DOI: 10.1038/sj.onc.1209786. View

13.

Leiderman Y, Kiss S, Mukai S . Molecular genetics of RB1--the retinoblastoma gene. Semin Ophthalmol. 2007; 22(4):247-54. DOI: 10.1080/08820530701745165. View

14.

Tomar A, Finger P, Gallie B, Kivela T, Mallipatna A, Zhang C . Global Retinoblastoma Treatment Outcomes: Association with National Income Level. Ophthalmology. 2020; 128(5):740-753. DOI: 10.1016/j.ophtha.2020.09.032. View

15.

Sant M, Capocaccia R, Badioni V . Survival for retinoblastoma in Europe. Eur J Cancer. 2001; 37(6):730-5. DOI: 10.1016/s0959-8049(01)00011-9. View

16.

MacCarthy A, Bayne A, Brownbill P, Bunch K, Diggens N, Draper G . Second and subsequent tumours among 1927 retinoblastoma patients diagnosed in Britain 1951-2004. Br J Cancer. 2013; 108(12):2455-63. PMC: 3694232. DOI: 10.1038/bjc.2013.228. View

17.

Kleinerman R, Schonfeld S, Sigel B, Wong-Siegel J, Gilbert E, Abramson D . Bone and Soft-Tissue Sarcoma Risk in Long-Term Survivors of Hereditary Retinoblastoma Treated With Radiation. J Clin Oncol. 2019; 37(35):3436-3445. PMC: 7001778. DOI: 10.1200/JCO.19.01096. View

18.

Schefler A, Abramson D . Retinoblastoma: what is new in 2007-2008. Curr Opin Ophthalmol. 2008; 19(6):526-34. DOI: 10.1097/ICU.0b013e328312975b. View

19.

Chantada G, Dunkel I, Qaddoumi I, Antoneli C, Totah A, Canturk S . Familial retinoblastoma in developing countries. Pediatr Blood Cancer. 2009; 53(3):338-42. DOI: 10.1002/pbc.21970. View

20.

Villanueva G, Sampor C, Moreno F, Alderete D, Moresco A, Pinto N . Subsequent malignant neoplasms in the pediatric age in retinoblastoma survivors in Argentina. Pediatr Blood Cancer. 2022; 69(8):e29710. DOI: 10.1002/pbc.29710. View